Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DURAGESIC-25 vs ALFENTA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Fentanyl is a mu-opioid receptor agonist that produces analgesia and sedation by mimicking endogenous opioids in the central nervous system.
μ-opioid receptor agonist that activates G-protein coupled receptors to inhibit adenylate cyclase, decreasing c AMP production, leading to reduced neuronal excitability and pain transmission.
Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate (FDA),Breakthrough pain in cancer patients (off-label),Anesthesia (off-label)
Induction and maintenance of anesthesia,Analgesic supplement during surgical procedures,Intravenous use for monitored anesthesia care (MAC)
Apply 25 mcg/hour transdermally every 72 hours; initial dose in opioid-naive patients: 25 mcg/hour is not recommended; use lower strength or immediate-release opioid first.
Intravenous: Initial dose 8-20 mcg/kg (0.5-1 min) then 0.5-3 mcg/kg/min or 3-5 mcg/kg q5-20min. For short procedures: 8-20 mcg/kg. For longer procedures: 50-75 mcg/kg followed by 0.5-3 mcg/kg/min.
Terminal elimination half-life 22-25 hours (range 13-31 h) after 72-h transdermal application; prolonged in elderly, hepatic or renal impairment
Terminal elimination half-life: 90–111 minutes (1.5–1.85 hours); prolonged in hepatic impairment.
Primarily metabolized via CYP3A4 to norfentanyl (major inactive metabolite) and other minor metabolites.
Hepatic via CYP3A4 to inactive metabolites; major metabolite is desmethylalfentanil (inactive).
Renal (75% as metabolites, <10% unchanged); fecal (9%)
Primarily renal (urinary) elimination as metabolites; approximately 80% recovered in urine, 20% in feces.
~80-85% bound to plasma proteins (mainly albumin, also alpha-1-acid glycoprotein)
Approximately 92% bound, primarily to alpha-1 acid glycoprotein and albumin.
6-10 L/kg (large, indicating extensive tissue distribution; Vd 6.4 L/kg in adults)
0.5–1.0 L/kg; reflects moderate tissue distribution; higher Vd in neonates and elderly.
Transdermal: ~92% absolute bioavailability (fentanyl absorbed through skin; compared to IV administration)
Intravenous: 100%; intramuscular: approximately 90%; intrathecal: approximately 10% (due to systemic absorption following spinal administration).
For GFR 10-50 m L/min: start with 12 mcg/hour patch; for GFR <10 m L/min: avoid use due to accumulation of active metabolite; consider alternative therapy.
No specific dose adjustment is recommended for renal impairment; however, alfentanil is primarily metabolized in the liver and its pharmacokinetics are not significantly altered in renal failure.
Child-Pugh Class A or B: reduce starting dose by 50% (e.g., start with 12 mcg/hour); Child-Pugh Class C: avoid use or use with extreme caution and close monitoring.
In hepatic impairment (Child-Pugh class A, B, C): Reduce dose by 50% and titrate carefully due to prolonged elimination half-life. Consider lower initial doses and extended dosing intervals.
For children aged 2-16 years: initial dose based on opioid tolerance; typical starting dose for opioid-naive: 25 mcg/hour transdermal patch every 72 hours is not recommended; use lower strength or immediate-release opioids; refer to institutional guidelines.
Children (1-12 years): Induction of anesthesia: 10-20 mcg/kg IV; maintenance: 5-10 mcg/kg IV or infusion 0.5-1 mcg/kg/min. For neonates and infants: Dose individualization required; titrate to effect.
Start at lowest available strength (12 mcg/hour) and titrate cautiously; monitor for respiratory depression and constipation; avoid in frail elderly if possible.
Elderly patients (>65 years): Reduce initial dose by 30-50% and administer slowly. Due to decreased clearance and increased sensitivity, lower infusion rates (e.g., 0.3-0.5 mcg/kg/min) may be needed.
WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF DURAGESIC. Ensure accuracy when prescribing, dispensing, and administering DURAGESIC. Dosage errors can result in accidental overdose or death. Concomitant use with CYP3A4 inhibitors, potent CYP3A4 inducers, or the cessation of CYP3A4 inducers can cause fatal respiratory depression. DURAGESIC is contraindicated in opioid-non-tolerant patients and in acute or postoperative pain.
Risk of respiratory depression, particularly in elderly or debilitated patients. Concomitant use with benzodiazepines or other CNS depressants may cause profound sedation, respiratory depression, coma, and death.
Life-threatening respiratory depression,Accidental exposure to children,Neonatal opioid withdrawal syndrome,Risks from concomitant use with benzodiazepines or other CNS depressants,Interaction with alcohol,Adrenal insufficiency,Hypotension and bradycardia,Severe hypotension,Risks in patients with gastrointestinal obstruction,Seizures in patients with seizure disorders,Life-threatening QT prolongation at high doses
Respiratory depression; abuse potential; hypotension; bradycardia; muscle rigidity; serotonin syndrome with concurrent serotonergic drugs; adrenal insufficiency; risk of withdrawal with prolonged use.
Opioid non-tolerant patients,Acute or short-term pain,Postoperative pain,Significant respiratory depression,Acute or severe bronchial asthma,Known or suspected gastrointestinal obstruction,Known hypersensitivity to fentanyl or any component of the system
Hypersensitivity to alfentanil or any component; significant respiratory insufficiency; severe asthma; paralytic ileus; concurrent use of MAOIs (or within 14 days); acute or postoperative pain management in children (except for procedural sedation).
Avoid alcohol and other CNS depressants (e.g., benzodiazepines) as they increase the risk of respiratory depression and sedation. No specific food interactions; however, grapefruit juice may theoretically increase fentanyl levels via CYP3A4 inhibition, but clinical significance is minimal. Advise patients to maintain consistent dietary habits.
No known interactions with food. However, grapefruit juice may increase alfentanil serum concentrations due to CYP3A4 inhibition; avoid concurrent consumption.
First trimester: Limited human data; animal studies show increased risk of malformations at high doses. Second/third trimester: Prolonged use may cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth. Avoid unless benefits outweigh risks.
Alfentanil, a short-acting opioid analgesic, is classified as FDA Pregnancy Category C. No well-controlled studies in pregnant women exist. In animal studies, no teratogenic effects were observed at clinically relevant doses; however, high doses caused embryotoxicity and increased fetal mortality. Trimester-specific risks: First trimester - potential for minor malformations based on limited human data; second trimester - possible risk if used chronically; third trimester - prolonged use may lead to neonatal respiratory depression, withdrawal syndrome, or opioid dependence. Use only if benefits outweigh risks.
Fentanyl is excreted in breast milk; M/P ratio approximately 1.0. Limited data suggest low infant exposure with maternal therapeutic doses, but risk of sedation/respiratory depression in infants. Use with caution; monitor infant for drowsiness and feeding difficulties.
Alfentanil is excreted into human breast milk in low concentrations. The milk-to-plasma (M/P) ratio is approximately 0.3. Estimated infant dose is <1% of maternal weight-adjusted dose, which is considered clinically insignificant. However, due to potential for neonatal opioid effects, caution is advised; monitor infant for drowsiness, respiratory depression, and feeding difficulties. Consider alternative analgesics with established safety profiles, such as acetaminophen or ibuprofen, for lactation.
No established dose changes; pharmacokinetics in pregnancy show increased clearance and volume of distribution. Individualize dosing based on pain severity and response; monitor for under- or overdosing. Titrate to effect with caution.
Pregnancy can alter pharmacokinetics of alfentanil. Increased plasma volume and distribution may require higher doses to achieve same effect, while decreased plasma protein binding may increase free fraction, potentiating effects. Alpha-1-acid glycoprotein levels change in pregnancy, affecting binding. In third trimester, clearance may be increased by up to 50% due to enhanced hepatic metabolism. Therefore, dose adjustments may be needed: consider starting at low dose and titrating to effect, with close monitoring. For intravenous administration, typical adult doses (5-20 μg/kg) may need adjustments; no standard pregnancy-specific dosing exists. Use the lowest effective dose for the shortest duration. In labor, avoid high doses prior to delivery due to risk of neonatal respiratory depression.
DURAGESIC-25 delivers fentanyl at 25 mcg/h transdermally. The reservoir system may leak if cut, potentially causing fatal overdose. Apply to non-irritated, non-hairy skin on upper torso. Do not apply heat sources (heating pads, hot tubs) as they increase absorption rate. Onset of action is 12-24 hours; titrate no more frequently than every 3 days. Use only in opioid-tolerant patients due to risk of respiratory depression. Monitor for serotonin syndrome if co-administering serotonergic drugs.
Alfentanil is a potent, rapid-onset, short-acting opioid analgesic used primarily for induction and maintenance of anesthesia. Due to its high protein binding (90%) and rapid redistribution, it has a shorter duration of action than fentanyl, making it suitable for brief, painful procedures. It undergoes hepatic metabolism via CYP3A4, so concomitant use with CYP3A4 inhibitors like ketoconazole or erythromycin can prolong its effects. Use caution in elderly or hypovolemic patients due to increased risk of hypotension. Naloxone reverses respiratory depression. Alfentanil is 5-10 times less potent than fentanyl.
Apply the patch to clean, dry, non-hairy skin on the upper body; change every 72 hours.,Do not cut, tear, or damage the patch; do not use if the pouch seal is broken.,Avoid exposing the patch area to direct heat sources such as heating pads, electric blankets, hot tubs, or prolonged sun exposure.,Keep patches out of reach of children and pets; dispose of used patches by folding adhesive sides together and flushing down the toilet.,Do not stop using this medication abruptly; withdrawal may occur.
This medication is given only by a healthcare professional in a hospital or surgical setting.,You may feel drowsy, dizzy, or nauseated after receiving this drug.,Report any difficulty breathing or slow heart rate to your healthcare provider immediately.,Avoid alcohol and sedatives for 24 hours after administration, as they can increase side effects.,Do not drive or operate machinery until the effects have fully worn off.
No interactions on record
"Propantheline, an anticholinergic agent, can competitively antagonize muscarinic acetylcholine receptors, potentially reducing gastrointestinal motility and secretion. Alfentanil, a mu-opioid receptor agonist, also decreases gastrointestinal motility through central and peripheral opioid receptors. Concomitant use may synergistically inhibit peristalsis, leading to severe constipation, paralytic ileus, or delayed gastric emptying, which can increase the risk of aspiration and complicate anesthesia recovery."
"Alfentanil, a potent opioid analgesic, can cause significant hypotension and respiratory depression. When combined with furosemide, a loop diuretic that reduces blood volume and vascular resistance, there is a synergistic decrease in blood pressure, which may precipitate cardiovascular collapse, especially in patients with compromised circulatory reserves. Additionally, furosemide may enhance the sedative and respiratory depressant effects of alfentanil, leading to increased risk of respiratory acidosis and altered mental status."
"Alfentanil, a potent mu-opioid receptor agonist, can enhance the bradycardic effects of nebivolol, a beta-1 selective blocker with additional nitric oxide-mediated vasodilation. The combination may lead to excessive slowing of heart rate, reduced cardiac output, and potential hemodynamic instability, particularly in patients with underlying cardiac conduction abnormalities or hypovolemia."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DURAGESIC-25 vs ALFENTA, answered by our medical review team.
DURAGESIC-25 is a Opioid Analgesic that works by Fentanyl is a mu-opioid receptor agonist that produces analgesia and sedation by mimicking endogenous opioids in the central nervous system.. ALFENTA is a Opioid Analgesic that works by μ-opioid receptor agonist that activates G-protein coupled receptors to inhibit adenylate cyclase, decreasing c AMP production, leading to reduced neuronal excitability and pain transmission.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DURAGESIC-25 and ALFENTA depend on the specific clinical indication. These are both Opioid Analgesic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DURAGESIC-25 is: Apply 25 mcg/hour transdermally every 72 hours; initial dose in opioid-naive patients: 25 mcg/hour is not recommended; use lower strength or immediate-release opioid first.. The standard adult dose of ALFENTA is: Intravenous: Initial dose 8-20 mcg/kg (0.5-1 min) then 0.5-3 mcg/kg/min or 3-5 mcg/kg q5-20min. For short procedures: 8-20 mcg/kg. For longer procedures: 50-75 mcg/kg followed by 0.5-3 mcg/kg/min.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DURAGESIC-25 and ALFENTA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DURAGESIC-25 is classified as Category C. First trimester: Limited human data; animal studies show increased risk of malformations at high doses. Second/third trimester: Prolonged use may cause neonatal opioid withdrawal s. ALFENTA is classified as Category C. Alfentanil, a short-acting opioid analgesic, is classified as FDA Pregnancy Category C. No well-controlled studies in pregnant women exist. In animal studies, no teratogenic effect. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.